PW MEDTECH GROUP DL-0001 risk profile
35 Normal where most of the sector sits
Measured 21 October 2026 from PWE's filed statements. Recomputed nightly.
35 (Normal), driven by Market expectation at 88, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 88 | Acute | Stable | Drawdown from the 52-week high — 47.3% |
| Operating pressure | 55 | Elevated | Easing | Costs outgrowing revenue — +7.6 percentage points |
| Cash conversion | 16 | Contained | Stable | Capital spending against operating cash — 0.44x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -5.83x |
| Competitive position | 31 | Normal | Stable | R&D-intensity gap against peers — -23.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for PW MEDTECH GROUP DL-0001